The unexpected downregulation of CD133 in MDA-MB-231CM cells, contrasting with its upregulation in MCF7CM cells, challenges the universal applicability of CD133 as a cancer stem cell marker in breast cancer. This evidence concerns the gene PROM1 and breast carcinoma.